Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – National Bank Financial issued their Q3 2017 earnings estimates for Inovio Pharmaceuticals in a research report issued on Monday, according to Zacks Investment Research. National Bank Financial analyst M. Kornack anticipates that the company will post earnings of $0.23 per share for the quarter.
INO has been the subject of a number of other reports. BidaskClub lowered shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, October 27th. Citigroup Inc. began coverage on shares of Inovio Pharmaceuticals in a research report on Wednesday, September 6th. They issued a “buy” rating and a $10.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Inovio Pharmaceuticals in a research report on Friday, September 22nd. ValuEngine raised shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 11th. Finally, Aegis reaffirmed a “buy” rating and set a $14.00 price objective on shares of Inovio Pharmaceuticals in a research report on Tuesday, July 18th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the stock. Inovio Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of C$19.16.
TRADEMARK VIOLATION WARNING: “Inovio Pharmaceuticals, Inc. (TSE:INO) to Post Q3 2017 Earnings of $0.23 Per Share, National Bank Financial Forecasts” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.dispatchtribunal.com/2017/11/12/inovalis-real-estate-investment-trust-ino-expected-to-earn-q3-2017-earnings-of-0-23-per-share.html.
Shares of Inovio Pharmaceuticals (INO) opened at C$4.74 on Wednesday. Inovio Pharmaceuticals has a 52-week low of C$4.40 and a 52-week high of C$9.86.
Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Wednesday, November 8th. The company reported C($0.40) EPS for the quarter, missing analysts’ consensus estimates of C($0.25) by C($0.15). The firm had revenue of C$2.60 million for the quarter, compared to analysts’ expectations of C$10.27 million. Inovio Pharmaceuticals had a negative net margin of 221.55% and a negative return on equity of 72.19%. Inovio Pharmaceuticals’s quarterly revenue was down 79.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.28) earnings per share.
A number of hedge funds have recently made changes to their positions in INO. Wasatch Advisors Inc. grew its holdings in Inovio Pharmaceuticals by 43.6% during the second quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the company’s stock valued at $20,469,000 after purchasing an additional 793,306 shares during the last quarter. Vanguard Group Inc. grew its holdings in Inovio Pharmaceuticals by 7.9% during the first quarter. Vanguard Group Inc. now owns 3,098,055 shares of the company’s stock valued at $20,510,000 after purchasing an additional 226,861 shares during the last quarter. Candriam Luxembourg S.C.A. acquired a new position in Inovio Pharmaceuticals during the second quarter valued at approximately $1,411,000. GSA Capital Partners LLP acquired a new position in Inovio Pharmaceuticals during the second quarter valued at approximately $1,035,000. Finally, Virtu KCG Holdings LLC acquired a new position in Inovio Pharmaceuticals during the second quarter valued at approximately $556,000. Institutional investors own 25.04% of the company’s stock.
The business also recently declared a monthly dividend, which was paid on Monday, October 16th. Shareholders of record on Friday, September 29th were issued a dividend of $0.069 per share. The ex-dividend date was Thursday, September 28th. This represents a $0.83 annualized dividend and a yield of 17.47%.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Get a free copy of the Zacks research report on Inovio Pharmaceuticals (INO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.